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STATEMENT OF TRANSLATIONAL RELEVANCE  
Androgen receptor (AR) N-terminal domain (NTD) contains activation function-1 (AF-1), which 
is a viable therapeutic target for castration-resistant prostate cancer (CRPC). AF-1 antagonists, 
such as EPI, have potential to overcome all currently proposed AR-related mechanisms of 
resistance. Compelling evidence indicate that gain-of-function mutations in AR ligand-binding 
domain (LBD) and constitutively active AR splice variant V7 (AR-V7) with truncated LBD are 
associated with resistance to abiraterone and enzalutamide. Here we demonstrate that EPI 
overcomes these clinically relevant AR-mechanisms of resistance that may drive CRPC that 
include overexpressed AR coactivators, gain-of-function AR mutations, and expression of 
constitutively active AR-V7. These results support the development of antagonists to AR AF-1 
for the clinical management of CRPC. EPI is the first inhibitor that binds to the NTD of any 
steroid hormone receptor to be tested in clinical trials and is initially aimed at CRPC patients that 
have failed abiraterone or enzalutamide (ClinicalTrials.gov Identifier: NCT02606123).  
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ABSTRACT  
Purpose: Persistent androgen receptor (AR) transcriptional activity is clinically evident in 
castration-resistant prostate cancer (CRPC). Therefore, AR remains as a viable therapeutic target 
for CRPC. All current hormonal therapies target the C-terminus ligand-binding domain (LBD) of 
AR. By using EPI to target AR activation function-1 (AF-1), in the N-terminal domain (NTD) 
that is essential for AR transactivation, we evaluate the ability of EPI to overcome several 
clinically relevant AR-related mechanisms of resistance. 
  
Experimental Design: To study the effect of EPI on AR transcriptional activity against 
overexpressed co-activators such as SRC1-3 and p300, luciferase reporter assays were performed 
using LNCaP cells. AR-negative COS-1 cells were employed for reporter assays to examine if 
the length of polyglutamine tract affects inhibition by EPI. The effect of EPI on constitutively 
active AR splice variants was studied in LNCaP95 cells, which express AR-V7 variant. To 
evaluate the effect of EPI on the proliferation of LNCaP95 cells, we performed in vitro BrdU 
incorporation assay and in vivo studies using xenografts in mice. 
  
Results: EPI effectively overcame several molecular alterations underlying aberrant AR activity, 
including overexpressed coactivators, AR gain-of-function mutations, and constitutively active 
AR-V7. EPI inhibited AR transcriptional activity regardless of the length of polyglutamine tract. 
Importantly, EPI significantly inhibited the in vitro and in vivo proliferation of LNCaP95 
prostate cancer cells, which are androgen-independent and enzalutamide-resistant.  
  
 5
Conclusion: These findings support EPI as a promising therapeutic agent to treat CRPC, 
particularly against tumors driven by constitutively active AR splice variants that are resistant to 
LBD-targeting drugs. 
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INTRODUCTION  
Most prostate cancers require androgen receptor (AR) transcriptional activity for survival 
and growth, and therefore, inhibiting androgen synthesis and AR transcriptional activity are the 
therapeutic approaches to treat advanced prostate cancer. These hormone therapies consist of 
androgen deprivation therapy (ADT) and application of antiandrogens. Unfortunately, within 12-
33 months most patients treated with hormone therapies relapse with a more aggressive and 
lethal form of the disease referred to as metastatic castration-resistant prostate cancer (mCRPC) 
(1). mCRPC is associated with poor prognosis and a mean survival time of 18-36 months (2).  
Despite ADT achieving castrate levels of serum testosterone, CRPC is associated with 
aberrantly restored AR transcriptional activity. The clinical onset of CRPC is characterized by a 
rise in serum levels of prostate-specific antigen (PSA), which is a gene regulated by AR. There 
are several possible mechanisms underlying continued transactivation of AR, including 
amplification of AR (3), gain-of-function mutations within the ligand binding domain (LBD) of 
AR that enables activation by nonandrogenic steroids or antiandrogens (4, 5), ligand-independent 
activation of the AR N-terminus domain (NTD) (6-9), overexpression of AR coactivators (10-
14), intratumoral de novo synthesis of androgens (15), and expression of constitutively active AR 
splice variants with truncated LBD (16, 17). AR mechanisms of resistance to abiraterone and 
enzalutamide also include expression of constitutively active AR splice variants, elevated 
intratumoral androgen, and AR LBD gain-of-function point mutations (18, 19). Thus novel 
approaches beyond AR LBD inhibition are required to block AR transcriptional activity for the 
treatment of mCRPC. One such approach involves targeting AR NTD which would theoretically 
block all of the above AR mechanisms of resistance.  
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Activation function-1 (AF-1) in AR NTD is essential for AR transcriptional activity (20) 
and thus a viable therapeutic target for CRPC. An antagonist of AR AF-1, EPI-002 (2R, 20S) is a 
single stereoisomer of the EPI-001 mixture (21). EPI-001, its stereoisomers and analogues 
(referred to herein as EPI) all effectively inhibit the growth of CRPC xenografts in mice (21, 22). 
Specificity and the mechanism of action of EPI has been elucidated; it specifically binds to Tau5 
of AR AF1 to block essential protein-protein interactions required for transcriptional activity of 
AR (21-24). Although at unusually high concentrations of up to 33 times its IC50 and at a non-
physiological pH of 9.4, EPI can have artifactual off-target effects (25). Here, we provide 
evidence that EPI can effectively inhibit aberrant AR transcriptional activity by mechanisms 
suggested to drive mCRPC such as overexpression of coactivators, AR gain-of-function 
mutations, and constitutively active AR splice variant.  First-in-Human Phase 1/2 clinical trials 
with EPI-506 (prodrug of EPI-002) are ongoing in Canada and US (ClinicalTrials.gov Identifier: 
NCT02606123). 
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MATERIALS AND METHODS 
 
Cell lines, transfection, and proliferation assay 
LNCaP cells were from Dr. Leland Chung (Cedars-Sinai Medical Center, Los Angeles, CA). 
LNCaP95 cells were from Dr. Stephen R. Plymate (University of Washington, Seattle, WA). 
COS-1 cells were from Dr. Rob Kay (Terry Fox Laboratory, Vancouver, BC). LNCaP and COS-
1 cells were not further authenticated in our laboratory, but were regularly tested to ensure 
mycoplasma-free (VenorTMGeM Mycoplasma Detection Kit, Sigma-Aldrich, St. Louis, MO). In 
September 2013, LNCaP95 cells were authenticated by short tandem repeat analysis and tested 
to ensure mycoplasma-free at DDC Medical (Fairfield, OH). All cells used were passaged less 
than 3 months after resuscitation. Transfection for luciferase reporter assays and cell 
proliferation assay were previously described (22). Details of transfection, proliferation assay, 
and plasmids and reagents are in the Supplementary Materials and Methods. 
 
Western blot analysis 
SRC-1, SRC-2 (TIF2), and SRC-3 (AIB-1) were probed with purified mouse anti-SRC-1, anti-
TIF2, and anti-AIB-1, respectively (BD Biosciences, Franklin Lakes, NJ). p300 was probed 
using p300 antibody (C-20) (Santa Cruz Biotechnology, Dallas, TX). AR was probed by anti-
androgen receptor antibody N-20 (Santa Cruz Biotechnology). Membranes were probed for β-
actin using monoclonal mouse anti-β-actin antibody (ab8226 from Abcam, Cambridge, MA).  
 
Protein-protein interaction studies 
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Cell-free SRC1-3 and AR interactions were analyzed on a Scintistrip microtitre 96-well plate 
(PerkinElmer Life Sciences) utilizing both purified recombinant AR-AF1 and in vitro 
transcribed/translated 35S-labelled binding partners, SRC-1a-CTD (amio acids 977 to 1240), 
SRC2-CTD (amino acids 1120-1464) and SRC3-CTD (amino acids 1093-1412) (26). Cell-based 
immunoprecipitation assay was also employed to study SRC and AR interactions with details in 
Supplementary Materials and Methods.  
 
Endogenous expression of genes regulated by AR  
48 hours after treatment, total RNA was extracted by using RNeasy® Micro Kit (QIAGEN, 
Valencia, CA), and reverse transcribed to cDNA by SuperScript®III First-Strand Synthesis 
System for RT-PCR (InvitrogenTM). Diluted cDNA and gene-specific primers were combined 
with Platinum ® SYBR® Green qPCRSuperMix-UDG with ROX (InvitrogenTM). Transcripts 
were measured by quantitative real-time (qRT)-PCR ABI PRISM 7900 Sequence Detection 
System (ABI PRISM®, Applied Biosystems by Life Technologies) in triplicates for each 
biological sample. Gene expression levels were normalized to housekeeping gene RPL13A. 
Primers have been described (22, 27). 
 
Xenografts and animal study approval 
Male NOD-SCID mice at 6-8 weeks old were subcutaneously injected with LNCaP95 cells (10 
million cells per site) using Matrigel (Becton Dicksinson, New Jersey). Mice were castrated 
when tumors volumes reached approximately 100 mm3. Drug treatment started one week after 
castration. Animals bearing LNCaP95 xenografts were randomized and administered with 100 
mg/kg body weight of EPI-002 twice daily (b.i.d.), or 50 mg/kg body weight of enzalutamide 
 10
once daily (q.d.), or vehicle control (CMC/DMSO) q.d. by oral gavage. Tumors were excised 2 
days after the last treatment. All animal studies conformed to the relevant regulatory and ethical 
standards. The University of British Columbia Animal Care Committee approved all experiments 
involving animals.  
 
Steroid levels in xenografts and immunohistochemistry 
Tumors were removed and 30-50 mg flash frozen for intratumoral steroid measurements as 
reported (18) and in the Supplementary Materials and Methods.  
 
Statistics  
Comparisons between two groups were performed with unpaired 2-tailed Student’s t test, and 
comparisons between three or more groups were performed using One-way or Two-way 
ANOVA (GraphPad Software, V6). A p value less than 0.05 was considered statistically 
significant.  
 11
RESULTS  
 
EPI maintains effective inhibition of AR transcriptional activity despite elevated levels of 
coactivators 
Elevated levels of AR coactivators such as the p160 steroid receptor coactivator (SRC) family 
proteins (SRC-1, SRC-2, and SRC-3) and CBP/p300 are associated with prostate cancer 
progression and poor prognosis (10-14). SRC and CBP/p300 directly interact with AR NTD (8, 
26, 28, 29). EPI blocks interaction of AR with CBP (22), but it is unknown if EPI also blocks 
interaction of AR with SRC. To test this, two approaches were employed. The first approach 
measured interaction in a cell-free assay with recombinant AR AF1 and SRC1,2,3-CTD proteins. 
This approach showed that EPI does not inhibit interaction between AF-1 and any of the SRC 
family members (Figure 1A). The second approach was to immunoprecipitate endogenous 
protein complexes from LNCaP cells with and without EPI treatment. These studies also showed 
no effect of EPI on this interaction (Figure 1B). Thus EPI does not block interaction of AR with 
the SRC family of coactivators. To test if EPI could maintain inhibition of AR transcriptional 
activity when SRC1-3 proteins were overexpressed, AR-driven PSA-luciferase reporter assays 
were performed in LNCaP cells transiently transfected with increasing amounts of SRC 
expression vectors. Consistent with previous studies (8), overexpression of each of the SRC 
family proteins resulted in a dose-dependent increase of androgen-induced AR transcriptional 
activity (Figure 1C, left panel). Western blot analysis confirmed the overexpression of each of 
the co-activators when compared to endogenous levels (Figure 1C, right panel). Despite the 
increase of androgen-induced AR transcriptional activity as a result of overexpressed SRC 
family proteins, enzalutamide and EPI both maintained effective and consistent inhibition of AR 
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activity, as indicated by the unchanged percentage of inhibition (Figure 1C, middle panel). 
Similarly, overexpression of p300 led to a dose-dependent increase of androgen-induced AR 
transcriptional activity in LNCaP cells (Figure 1D, left panel). Western blot analysis confirmed 
increased expression of p300 when compared to endogenous levels (Figure 1D right panel). Both 
EPI and enzalutamide effectively inhibited AR transcriptional activity in spite of elevated levels 
of p300 (Figure 1 D, middle panel). 
 
Inhibition of AR transcriptional activity by EPI is not affected by polymorphic lengths of 
polyglutamine tract 
The human AR gene contains a polymorphic CAG triplet repeat within exon 1 that encodes for a 
polyglutamine tract in its NTD . The number of CAG repeats ranges between 6–36 in the human 
population (30).  Since EPI binds AF-1 in the NTD, we tested whether variable lengths of 
polyglutamine tract would affect the efficacy of EPI to inhibit AR transcriptional activity. AR-
negative COS-1 cells were co-transfected with plasmids containing AR-driven probasin (PB)-
LUC reporter and expression vectors encoding human full-length AR with polyglutamine tract 
containing 0, 12, 20, 40, or 49 contiguous glutamines. Regardless of the length of polyglutamine 
tract, EPI demonstrated consistent inhibition of androgen-induced AR transcriptional activity 
(Figure 2A, 2B). Consistent with previously published studies (30), these data confirmed the 
inverse correlation of the length of polyglutamine tract and AR transcriptional activity (Figure 
2C). Western blot analysis revealed that levels of ectopic AR expressed in COS-1 cells were 
within physiological levels comparable with the endogenous AR level in LNCaP cells (Figure 
2D). However, expression of AR with 49 repeats of glutamine (CAG49) was reduced compared 
to the other ARs with shorter tracts. Enzalutamide reduced the total protein levels of AR 
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consistent with previous reports (31). These results support that variable lengths of 
polyglutamine tract within the NTD did not diminish inhibition of AR transcriptional activity by 
EPI. 
 
EPI inhibits transcriptional activities of AR with clinically relevant mutations 
To assess the effectiveness of EPI against the transcriptional activities of several clinically 
relevant AR gain-of-function mutations including mutations found in both the NTD and LBD, 
we performed AR-driven reporter gene assays using AR-negative COS-1 cells transiently co-
transfected with various AR mutants and treated the cells with different inhibitors. First, we 
examined two AR NTD gain-of-function mutations derived from patients treated with 
antiandrogens. AR E255K interacts with an E3 ubiquitin ligase and enhances protein stability 
and androgen-independent nuclear localization (32). AR W435L increases interaction between 
the AR NTD and LBD (32). EPI significantly inhibited androgen-dependent transcriptional 
activities of these two AR NTD mutations, and the level of inhibition achieved was similar to 
that of the wild-type (WT) AR (Figure 3A). This suggests that these NTD gain-of-function 
mutations did not impair the effectiveness of EPI to block transcriptional activity of AR. Next, 
we tested several AR LBD gain-of-function mutations. In the absence of androgen, EPI had no 
agonist activity which was contrary to hydroxyflutamide and bicalutamide that stimulated 
substantial AR transcriptional activities for WT AR and the mutants tested (Figure 3A). 
Enzalutamide also did not stimulate AR activity in the absence of androgen with any of these 
mutants. In the presence of androgen, EPI significantly blocked the transcriptional activities of 
WT, V715M, R761G, H874Y, and T877A (Figure 3A). Hydroxyflutamide failed to significantly 
block androgen-dependent transcriptional activities of AR H874Y and T877A, which is 
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consistent with previous reports that these two mutants confer resistance to flutamide (4, 33). No 
statistical significance was measured for the percentage of inhibition of androgen-dependent AR 
transcriptional activities between enzalutamide and EPI, with the exception of WT AR and AR 
T877A, in which enzalutamide displayed stronger inhibition (Figure 3B). Relative levels of 
ectopic expression of each of the AR mutants are shown in Figure 3C. 
 
EPI blocks the non-canonical transcriptional program regulated by constitutively active 
AR splice variant 
Expression of LBD-truncated and constitutively active AR splice variants AR-V7 or AR-V567es 
is associated with poor prognosis (17, 34). EPI inhibits the activities of AR-V567es in the 
presence and absence of full-length AR while antiandrogens, including enzalutamide, have no 
effect (21). AR-V7 is reported to regulate a distinct transcriptional program compared to full-
length AR (35-37). Any AR LBD-targeting therapies including enzalutamide may not inhibit 
AR-V7’s transcriptional activity and thus may have no effect on expression of AR-V7’s 
transcriptome. However, an inhibitor of AR AF-1, such as EPI should block AR-V7 
transcriptional activity and expression of its downstream target genes. To test this, the expression 
of genes regulated by full-length AR and AR-V7 was evaluated in LNCaP95 cells treated with 
antiandrogens or EPI. LNCaP95 cells express functional full-length AR and AR-V7 (16, 35). A 
PSA-luciferase assay confirmed that these cells do have a functional full-length AR that was 
responsive to androgen (Figure 4A). Androgen-induced PSA-luciferase reporter activities were 
inhibited by antiandrogens (bicalutamide and enzalutamide) and EPI. Consistent with LNCaP95 
cells expressing functional full-length AR as shown with the PSA-reporter gene construct, 
endogenous expression levels of PSA and FKBP5 were induced by androgen (Figure 4B). Both 
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enzalutamide and EPI decreased androgen-induced levels of PSA and FKBP5 transcript (Figure 
4B). Next we measured levels of mRNA of genes that are distinctively regulated by AR-V7 such 
as UBE2C, CDC20, and AKT1 (35). Firstly, expression of these genes was not induced by 
androgens thereby supporting that they were not regulated by full-length AR. Consistent with 
this interpretation, enzalutamide which blocks full-length AR, had no effect on the levels of 
expression of these genes (Figure 4C). Contrary to antiandrogens, EPI significantly reduced the 
levels of expression of UBE2C, CDC20, and AKT1 (Figure 4C). Levels of mRNA for full-length 
AR and AR-V7 were not significantly affected by enzalutamide or EPI (Figure 4D). Nor were 
protein levels of full-length AR or AR-V7 decreased by any of the treatments compared to 
relevant controls and androgen treatments (Figure 4E). These data support the ability of EPI to 
inhibit the transcriptional activities of full-length AR and constitutively active AR-V7 to block 
expression of their target genes. 
 
EPI attenuates the growth of enzalutamide-resistant LNCaP95 xenografts 
Proliferation of LNCaP95 cells is androgen-independent and driven by AR-V7 transcriptional 
activity (16, 35). Therefore if EPI blocks the transcriptional activity of AR-V7 as suggested here 
then EPI should also impact the proliferation of these cells. Consistent with previous reports, 
proliferation of LNCaP95 cells was androgen-independent and resistant to antiandrogens such as 
bicalutamide and enzalutamide (Figure 5A).  Consistent with EPI blocking AR-V7 
transcriptional activity, EPI significantly reduced the number of proliferating LNCaP95 cells. 
Together these data suggest LNCaP95 cells are enzalutamide-resistant yet sensitive to EPI by a 
mechanism involving inhibition of the transcriptional activity of AR-V7. To test in vivo effects 
of EPI on potentially enzalutamide-resistant tumors, LNCaP95 cells were grown as xenografts in 
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male SCID mice that were castrated prior to treatments. EPI significantly attenuated the growth 
of LNCaP95 xenografts, whereas enzalutamide had no significant effect (Figure 5B). By the end 
of the study, animals treated with EPI had xenografts that were significantly smaller than those 
treated with vehicle or enzalutamide. EPI reduced the tumor size by more than 50% compared to 
vehicle control (Figure 5C, D), but did not result in tumor regression of LNCaP95 xenografts 
contrary to regression achieved with EPI in LNCaP xenografts (21, 22). These studies 
demonstrate the in vivo efficacy of EPI on the growth of castration-resistant and enzalutamide-
resistant LNCaP95 tumors and support previous data showing the superior efficacy of EPI 
compared to antiandrogens on VCaP xenografts maintained in castrated hosts (21). Together 
these data are consistent with the notion that LNCaP95 tumors are driven by constitutively active 
AR-V7. Support for this can be provided by analysis of levels of expression of genes regulated 
by full-length AR and AR-V7 in the harvested xenografts. QPCR of RNA isolated from 
harvested tumors revealed that enzalutamide substantially increased levels of full-length AR and 
AR-V7 transcripts (Figure 5E), consistent with in vitro data (38), while EPI did not alter 
transcript levels of full-length AR or AR-V7. EPI treatment decreased levels of expression of 
genes regulated by full-length AR and AR-V7, including PSA, FKBP5, UBE2C, and UGT2B17 
(Figure 5E), consistent with the in vitro findings and gene expression data from VCaP xenografts 
maintained in castrated hosts treated with EPI (21). Measurement of androgen levels in these 
same xenografts confirms that LNCaP95 xenografts were not driven by androgen in castrated 
hosts (Figure 5F).  
Immunohistochemistry analysis of harvested xenografts revealed similar levels of total 
AR protein with all treatments (Figure 6A). EPI significantly decreased proliferation as indicated 
by the lowered number of Ki67 stained cells, while it significantly induced apoptosis as indicated 
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by the increased number of TUNEL positive cells (Figure 6B). Consistent with TUNEL staining, 
cleaved caspase-3 staining of these xenografts also showed significantly increased level of 
cleaved caspase-3 in EPI treatment group (Figure S1). In contrast, enzalutamide had no effect on 
the proliferation and apoptosis in these xenografts. In accordance with previously published data 
that enzalutamide increases AR-V7 protein expression in LNCaP95 cells (35), we observed 
stronger nuclear AR-V7 staining with enzalutamide treatment, while full-length AR staining was 
similar between the treatment groups (Figure S2). Together these data support the efficacy of 
EPI in blocking the growth of castration-resistant and enzalutamide-resistant tumors by a 
mechanism that is consistent with blocking the transcriptional activities of both full-length AR 
and constitutively active AR splice variants. 
 18
DISCUSSION 
Restoration of AR transcriptional activity is believed to be the major driver of most lethal 
mCRPC (39).  Discovery of new drugs that block persistent AR transcriptional activities is 
crucial for improving the clinical management of this disease.  In contrast to all current hormone 
therapies that act through AR C-terminal LBD, including abiraterone and enzalutamide, an 
antagonist of AR AF-1 in the NTD has the potential to block all known AR mechanisms of 
resistance. The present study revealed that EPI, an AF-1 antagonist, was capable of blocking 
such AR mechanisms of resistance. AR belongs to the steroid hormone receptor family that 
includes glucocorticoid receptor, progesterone receptor, estrogen receptor and mineralocorticoid 
receptor. These receptors share structural features such as LBD, DNA-binding domain, and an 
intrinsically disordered NTD. There are no small molecules reported that bind to NTDs of any 
other steroid hormone receptor. Thus EPI is precedent in the field of steroid hormone receptors 
as the first small molecule discovered that directly interacts with AR NTD (21, 22). AR 
transcriptional activity is dependent on a functional AF-1 region within its NTD which is 
comprised of Tau-1 (amino acid residues 110-370) and Tau-5 (amino acid residues 360-528). 
Tau-1 and Tau-5 may act independently of one another (20). EPI binds AF-1 (21, 22) and recent 
NMR spectroscopy has mapped its binding specifically to Tau-5 (24).  
AR interacts with p160 SRC coactivators through both its C-terminal LBD and AF-1 (40-42) and 
with CBP/p300 in its NTD (29). CBP/p300 are bridging factors that are necessary for AR 
transcriptional activity (29, 43). The expression levels of SRCs and CBP/p300 are increased in 
CRPC and these increases in expression are proposed as an AR mechanism of resistance to 
current hormone therapies (10-14). Here, we demonstrated the ability of EPI to maintain an 
effective and consistent inhibition of AR transcriptional activity in spite of elevated levels of 
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these AR coactivators. EPI did not block interaction of AF-1 with p160 SRCs using recombinant 
peptides or with endogenous proteins coimmunoprecipitated from cells. This implies that p160 
SRCs interaction with AF-1 cannot over-ride or compensate for the loss of interaction with CBP 
and RAP74 caused by EPI to decrease AR transcriptional activity (22). P300 and RAP74 interact 
with Tau-5 of AR AF-1 (24, 44). RAP74 is a subunit of transcriptional factor IIF (TFIIF) and an 
essential part of the basal transcriptional machinery to recruit RNA polymerase II that is 
necessary for transcription. Hence SRC interaction is not sufficient on its own to drive AR 
transcriptional activity in the absence of RAP74 and CBP/p300. 
The length of polyglutamine tract influences interaction of AR with corepressors and AR 
transcriptional activity (45). The AR repressor, silencing mediator for retinoic acid and thyroid 
hormone receptor (SMRT), binds Tau-5 and LBD, and its ability to repress AR activity is highly 
influenced by the length of AR polyglutamine tract with only 17% inhibition of AR with 9 
repeats and 56% of a AR with 42 repeats (45). Inhibition of AR transactivation by EPI was not 
affected by the length of polyglutamine tract within the NTD. EPI achieved significant and 
similar levels of inhibition of transactivation of AR with variable lengths of polyglutamine tract 
in the range of 0 to 49 repeats. The ability of EPI to continue to inhibit AR transcriptional 
activity in spite of differences in polyglutamine tract length is relevant to the clinical application 
of EPI to treat prostate cancer patients and particularly those patients with shorter polyglutamine 
tracts that correlate with more aggressive disease (46).    
AR LBD is a structurally ordered domain with an open conformation for ligand binding, 
making the binding pocket for antiandrogen readily accessible (47). Contrary to this, the NTD is 
intrinsically disordered and acts as a hub for interaction with many proteins. Such differences in 
protein structure between the LBD and NTD may explain the rapid efficacy of antiandrogens in 
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short-term in vitro inhibition of AR transcriptional activity compared to EPI in reporter assays. It 
may take longer, perhaps one doubling time, in order for the binding site in the NTD to be 
accessible to EPI. However, in long term in vivo studies, the activities of antiandrogen and EPI 
were comparable in xenografts that express solely full-length AR in spite of the short half-life of 
EPI relative to antiandrogens (24). AR W435L (Tau-5) and AR E255K (Tau-1) are both cell-
specific and reporter-specific gain-of-function AR NTD mutations that were originally detected 
using tissue from patients treated with antiandrogens (32). EPI effectively inhibited all the 
mutant gain-of-function ARs tested here, including E255K and W435L and several LBD 
mutations. The requirement of AF-1 for AR transcriptional activity supports a prediction that an 
antagonist to AF-1 should inhibit all LBD gain-of-function mutations.  
EPI binds AF-1 (21, 22) and within this region specifically to Tau-5 (24), which is 
especially important for ligand-independent transcriptional activity of constitutively active 
truncated AR lacking LBD (20). Consistent with EPI binding to Tau-5, functional assays show 
that EPI blocks the activity of ectopic constitutively active AR splice variant and truncated AR1-
653 deletion mutant (21, 22). LBD-truncated AR splice variants such as AR-V7 and AR-V567es 
are correlated with poor prognosis (34). Aberrant and persistent AR transcriptional activity 
caused by constitutively active AR splice variants is likely a main common mechanism of 
resistance to abiraterone and enzalutamide, and compelling evidence suggests that these variants 
provide resistance to current LBD-targeting therapies in vitro and in vivo (18, 38, 48). A recent 
clinical study revealed that the levels of AR-V7 in the circulating tumor cells from CRPC 
patients are correlated with resistance to abiraterone and enzalutamide (49). These findings 
indicate the potential of constitutively active AR variants to be a major mechanism of resistance 
to current AR LBD-targeting therapies, but more importantly, they highlight the need for 
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inhibitors of AR AF-1. In LNCaP95 cells, that endogenously express both functional full-length 
AR and AR-V7, EPI reduced the expression of genes regulated by full-length AR such as PSA 
and FKBP5 and most importantly genes distinctly regulated by AR-V7, such as UBE2C, and 
CDC20, while enzalutamide had no effect. Androgen-independent proliferation of LNCaP95 
cells was significantly reduced by EPI, while antiandrogens had no effect. Consistent with these 
in vitro results, in vivo EPI caused significant reduction of the growth of castration-resistant and 
enzalutamide-resistant LNCaP95 xenografts that recapitulate CRPC tumors driven by 
constitutively active AR splice variants lacking the LBD. Evidence for in vivo, on-target activity 
was provided by analysis of gene expression of the harvested xenografts showing EPI decreased 
expression of genes regulated by full-length AR and AR-V7. These results support previous 
findings that EPI specifically decreases the growth of castration-resistant VCaP xenografts that 
express AR-V7 splice variant with concomitant evidence of on-target activity provided by gene 
expression analysis (21). Thus, antagonists of the AF-1 such EPI represent a viable therapeutic 
approach to treatment CRPC tumours that are driven by AR splice variants, which have emerged 
as a clinically significant mechanism underlying the progression and therapy resistance in CRPC. 
EPI-506, a prodrug of EPI-002, is in clinical trials for patients that have failed abiraterone and 
enzalutamide with expression of AR-V7 proposed to be measured in circulating tumor cells (50).  
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FIGURE LEGENDS 
Figure 1. EPI overcomes aberrant AR transcriptional activity caused by overexpressed 
coactivators. (A) SRC1 and SRC3 show robust binding, while SRC2 shows relatively weak 
interactions with AR AF1. EPI-001 does not impair the binding of SRC1, 2 or 3. The inactive 
analogue compound 185-9-1 (B2H) was a control. The results are for two independent 
experiments measured in triplicate: SRC1 and SRC2 data was pooled (n=6), while SRC3 is a 
representative experiment (n=3). (B) EPI-001 does not block physical interaction between 
endogenous AR and SRC1 in LNCaP cells exposed to R1881 or vehicle (Ethanol). IP: 
immunoprecipitation; WB: western blotting. (C) LNCaP cells were co-transfected with PSA-
luciferase reporter (PSA6.1-LUC) and coactivators. Cells were pretreated with vehicle, 10µM 
enzalutamide (ENZ), or 25µM EPI (EPI-002) for 1 hr before the treatment of 1nM R1881 for 48 
hr. Luciferase activities were normalized to vehicle control treatment for SRC1, SRC2, SRC3, 
and (D) p300. Percentage of inhibition by treatments was plotted using R1881-treatment for 
normalization. Coactivator overexpression in LNCaP cells was confirmed by western blot 
analyses using specific antibodies with β-actin as a loading control. For the reporter assays, bar 
graphs are mean ± SEM with n ≥ 3 independent experiments.   
 
Figure 2. EPI inhibits polymorphic AR NTD with variable lengths of polyglutamine tract. 
COS-1 cells were co-transfected with PB-luciferase reporter and expression vectors containing 
AR with different lengths of polyglutamine tract. Cells were pretreated with vehicle, 10µM 
enzalutamide (ENZ), or 25µM EPI (EPI-002) for 1 hr prior to treatment of 1 nM R1881 for 24 
hr. (A) Luciferase activities for ARs were plotted in percentage of activation using vehicle-
R1881 treatment as normalization. (B) Percentage of inhibition by treatments was calculated 
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based on vehicle-R1881 treatment and plotted. (C) R1881-induced PB-LUC activity under 
vehicle treatment was plotted for each AR. (D) The expression levels of ARs transfected in COS-
1 cells were compared to LNCaP endogenous levels of AR by western blot using AR-N20. β-
actin was a loading control. Bar graphs are mean ± SEM with n ≥ 3 independent experiments. 
One-way ANOVA compared the treatment groups to vehicle-R1881 control in (A), and ARs 
with variable length of polyglutamine tract in (C); *p < 0.05; **p < 0.01; ***p < 0.001.  
 
Figure 3. EPI blocks the transcriptional activity of ARs with clinically relevant gain-of-
function mutations. COS-1 cells were co-transfected with PB-luciferase reporter and expression 
vectors containing wild-type (WT) AR and mutant AR. Cells were pretreated with vehicle, 
10µM enzalutamide (ENZ), 10µM bicalutamide (BIC), or 10µM hydroxyflutamide (FLU), or 
25µM EPI (EPI-002) for 1 hr prior to treatment of 1 nM R1881 or ethanol for 24 hr. (A) 
Luciferase activities were measured, and values were plotted after normalized to vehicle-ethanol 
treatment. (B) Percentage of inhibition by treatments was calculated based on vehicle-R1881 
treatment and plotted. Bar graphs are mean ± SEM with n ≥ 3 independent experiments. One-
way ANOVA compared treatment groups with vehicle controls in (A), and unpaired Student’s t 
test was used to compare EPI with ENZA in (B); *p < 0.05; **p < 0.01; ***p < 0.001. (C) 
Protein levels of ectopic expression of WT AR and AR mutants in COS-1 cells compared to 
endogenous levels of AR in LNCaP cells were shown in a representative western blot using anti-
AR N-20 antibody. β-actin was used as a loading control.  
 
Figure 4. EPI inhibits transcriptional activity of full-length AR and AR-V7 in LNCaP95 
cells. (A) LNCaP95 cells were transfected with AR-driven luciferase reporter PSA6.1-LUC and 
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pretreated with vehicle, 10µM enzalutamide (ENZ) or bicalutamide (BIC), or 25µM EPI (EPI-
002) for 1 hr prior to addition of 1 nM R1881 for 48 hr. Luciferase activities were measured, and 
values were plotted after normalized to vehicle-ethanol treatment. (B-E) LNCaP95 cells were 
treated the same as above. Levels of mRNA were measured and quantified for (B) canonical AR-
regulated genes PSA and FKBP5, (C) AR variant-regulated genes UBE2C and CDC20, and (D) 
full-length (FL) AR and AR-V7. Levels of expression for each gene were normalized to mRNA 
levels of RPL13A. (E) AR protein levels measured by western blot using AR-N20 antibody and 
β-actin as a loading control. Bar graphs are mean ± SEM with n ≥ 3 independent experiments. 
One-way ANOVA comparing treatment groups to vehicle controls; *p < 0.05; **p < 0.01; ***p 
< 0.001. 
 
Figure 5. EPI inhibits the growth of CRPC driven by AR variants. (A) LNCaP95 cells were 
pretreated with vehicle, 10µM bicalutamide (BIC), 10µM enzalutamide (ENZ), or 25µM EPI 
(EPI-002) for 1 hr prior to addition of 0.1 nM R1881 for 2 days. Proliferation was measured by 
bromodeoxyuridine (BrdU) incorporation. Bar graphs are mean ± SEM with n ≥ 3 independent 
experiments. Two-way ANOVA comparing treatment groups to vehicle controls; ****p < 
0.0001. (B) LNCaP95 tumor growth in castrated mice orally administered EPI (EPI-002) (n=4; 
100mg/kg body weight, b.i.d.), enzalutamide (n=3; 50 mg/kg body weight, q.d.) or vehicle 
control (n=3; CMC/DMSO, q.d.) for a total of 26 doses. (C) Final tumor volume on day 27 prior 
to harvesting. (D) Photographs of representative xenografts harvested on day 27. The white scale 
bar represents 1 cm. (E) Transcript levels of full-length (FL)-AR, AR-V7, PSA, UBE2C, 
FKBP5, and UGT2B17 normalized to RPL13A using total RNA isolated from the above 
LNCaP95 xenografts harvested on day 27. (F) Intra-tumoral steroid levels as determined by mass 
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spectroscopy, values are mean +/- SD in three tumors for each treatment. A significant decrease 
of testosterone and dihydrotestosterone following castration, p < 0.001, with no effects of EPI or 
enzalutamide on castrate steroid levels. There were no changes in dehydroepiandosterone 
(DHEA), androsterone, or 5-androstenedione (androst-5-ene-3,17-dione, or AED) pre- or post-
castration. 
 
Figure 6. EPI reduces proliferation and increases apoptosis in LNCaP95 xenografts.  
(A) Representative xenograft tumors stained for hematoxylin and eosin (HE), AR, Ki67 and 
TUNEL. Scale bars (red) indicate 20 µm. (B) % of Ki67 and % of TUNEL positive cells were 
counted in xenograft sections of each treatment. Total number of cells counted: 2361 (Control, 
Ki67), 2658 (EPI-002, Ki67), 2409 (ENZA, Ki67), 1209 (Control, TUNEL), 1210 (EPI-002, 
TUNEL) and 1137 (ENZA, TUNEL). Bar graphs are mean ± SEM with n = 3 different xenograft 
sections. One-way ANOVA comparing treatment groups to control; *p < 0.05; **p < 0.01.  
 






